Q-omics provides the consensus-scored TMEM31 profile across patient tissues and cancer cell-line models. TMEM31 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TMEM31 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, TMEM31 RNA expression shows 10,820 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, HNSC, and TGCT as cancer lineages where TMEM31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM31 survival associations across molecular data types. TMEM31 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM31 RNA expression–survival associations across cancer types. High TMEM31 expression shows unfavorable associations in BRCA, KIRP, HNSC, SCLC and TGCT, but favorable associations in CESC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TMEM31 RNA expression.
This table summarizes TMEM31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM31 shows lower tumor expression in HNSC, THCA, LUAD, LUSC and KIRP and higher tumor expression in CHOL. The HNSC box plot shows higher TMEM31 RNA expression in normal versus tumor tissue (log2 FC = −0.108, t-test p = .006).
This table shows molecular features associated with TMEM31 in patient tissues and cancer cell lines. In patient samples, TMEM31 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
